Canine Polymyositis: Diagnosis and Management

At a Glance

Canine polymyositis is an immune-mediated inflammatory myopathy producing generalized muscle weakness, atrophy, and dysphagia. Diagnosis requires integrating clinical signs, serum creatine kinase (CK) elevation, electromyography (EMG) abnormalities, and muscle biopsy histopathology. Management centers on immunosuppressive therapy with corticosteroids and adjunctive agents, supported by physical rehabilitation. The table below summarizes key diagnostic and management features.

Pathophysiology and Etiology

Canine polymyositis is an acquired, immune-mediated disorder in which the immune system targets skeletal muscle fibers. The inflammatory process involves infiltration of lymphocytes, macrophages, and plasma cells into the endomysium and perimysium, leading to myofiber necrosis, phagocytosis, and eventual muscle atrophy. The condition may occur as a primary idiopathic disorder or secondary to underlying diseases such as thymoma, neoplasia, or other immune-mediated conditions.

The pathogenesis involves both cell-mediated and humoral immune responses. Cytotoxic T lymphocytes directly damage muscle fibers expressing major histocompatibility complex class I antigens. Concurrently, autoantibodies against muscle components, including anti-type II myosin antibodies, may contribute to the inflammatory cascade. The trigger for this autoimmune response remains unknown in most cases, though genetic predisposition has been identified in certain breeds.

A hereditary form of polymyositis has been described in Dutch Kooiker dogs, with magnetic resonance imaging characteristics documented in affected individuals. This breed-specific presentation underscores the importance of considering genetic factors in the diagnostic evaluation.

The Merck Veterinary Manual provides general guidance on inflammatory myopathies in dogs, emphasizing the immune-mediated nature of these conditions. The World Organisation for Animal Health addresses animal health and welfare standards that apply to the management of chronic conditions in veterinary practice.

Clinical Presentation and Signalment

Signalment and Breed Predisposition

Canine polymyositis can affect dogs of any age, breed, or sex, though certain populations appear at increased risk. Large-breed dogs, including German Shepherd Dogs, Labrador Retrievers, and Golden Retrievers, are overrepresented in some case series. The condition typically presents in middle-aged to older dogs, with a median age of onset around 6 to 8 years. No consistent sex predilection has been identified.

A clinicopathologic review of 200 cases of canine inflammatory myopathies provides important epidemiologic data on breed and age distributions. The hereditary form in Dutch Kooiker dogs demonstrates that breed-specific presentations exist and should be considered during diagnostic evaluation.

History and Owner Observations

Owners typically report a progressive history of exercise intolerance, generalized weakness, and reluctance to jump or climb stairs. The onset may be acute or insidious, with clinical signs evolving over weeks to months. Key historical features include:

• Stiff or stilted gait that worsens with exercise
• Difficulty rising from recumbency
• Head drop or neck ventroflexion
• Dysphagia with regurgitation or gagging
• Voice change or loss of bark
• Muscle wasting, particularly over the temporal and masseter muscles
• Ptyalism and difficulty prehending food

Physical Examination Findings

The hallmark physical examination finding is generalized muscle weakness, often most pronounced in the proximal limb muscles and axial musculature. Affected dogs may exhibit a short-strided gait, muscle tremors, and a tendency to knuckle over on the paws. Muscle atrophy is common and may be symmetric or asymmetric, with the temporal, masseter, and epaxial muscles frequently affected.

Dysphagia is a critical finding that distinguishes polymyositis from other neuromuscular disorders. Affected dogs may have difficulty swallowing, with food and water falling from the mouth. Regurgitation secondary to esophageal dysfunction may occur, though megaesophagus is less common than in myasthenia gravis.

Neurologic Examination

The neurologic examination typically reveals normal mentation, cranial nerve function (except for dysphagia), and spinal reflexes. Proprioceptive deficits are absent unless concurrent neuropathy exists. The absence of sensory deficits and normal spinal reflexes helps differentiate polymyositis from peripheral neuropathies and spinal cord disorders.

Diagnostic Workup

Initial Laboratory Evaluation

Complete blood count and serum biochemistry profile are essential first steps. Serum creatine kinase (CK) is the most sensitive and specific biochemical marker for muscle injury. Elevations of 2 to 10 times the upper reference limit are typical, though normal CK does not exclude polymyositis. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) may also be elevated due to muscle origin, not hepatic disease.

The Merck Veterinary Manual provides reference information on laboratory interpretation for muscle disorders in dogs. Serial CK measurements are useful for monitoring disease activity and treatment response.

Electromyography

Electromyography (EMG) is a valuable diagnostic tool that can confirm the presence of an active myopathic process. Characteristic findings include abnormal spontaneous activity, such as fibrillation potentials, positive sharp waves, and complex repetitive discharges. These abnormalities are most pronounced in the proximal limb muscles, epaxial muscles, and muscles of mastication.

EMG also serves to guide muscle biopsy site selection. Muscles with the most severe EMG abnormalities are most likely to yield diagnostic histopathology. However, EMG findings are not specific to polymyositis and can be seen in other inflammatory myopathies and muscular dystrophies.

Muscle Biopsy

Muscle biopsy is the gold standard for definitive diagnosis. Biopsy samples should be obtained from muscles with EMG abnormalities or from clinically affected muscles, such as the triceps, biceps femoris, or temporal muscles. Samples must be handled carefully to avoid artifact, with submission to a laboratory experienced in neuromuscular histopathology.

Histopathologic findings include:

• Endomysial and perimysial inflammatory cell infiltrates (lymphocytes, macrophages, plasma cells)
• Myofiber necrosis and phagocytosis
• Myofiber regeneration (basophilic fibers with internal nuclei)
• Fiber size variation and atrophy
• Perifascicular atrophy (less common than in human dermatomyositis)

The distribution and character of inflammation help distinguish polymyositis from other inflammatory myopathies, such as masticatory muscle myositis, which selectively targets type 2M fibers in the muscles of mastication.

Autoantibody Testing

Serologic testing for autoantibodies may support the diagnosis of immune-mediated myositis. Anti-type II myosin antibodies have been identified in some dogs with polymyositis, though their sensitivity and specificity are not well established. Testing for antinuclear antibodies (ANA) and other autoantibodies may help identify concurrent immune-mediated disorders.

Advanced Imaging

Magnetic resonance imaging (MRI) can demonstrate muscle inflammation, edema, and atrophy in affected muscles. MRI findings include increased T2 signal intensity and contrast enhancement in affected muscles, reflecting active inflammation. While MRI is not required for diagnosis, it may be useful in cases with atypical presentation or when biopsy guidance is needed.

The magnetic resonance imaging characteristics of hereditary polymyositis in Dutch Kooiker dogs have been documented, providing a reference for imaging findings in this specific population.

Differential Diagnoses

The differential diagnosis for canine polymyositis includes:

• Masticatory muscle myositis (selective involvement of muscles of mastication)
• Myasthenia gravis (weakness improves with neostigmine administration)
• Infectious myositis (Neospora caninum, Toxoplasma gondii, bacterial)
• Muscular dystrophy (younger dogs, breed predisposition)
• Endocrine myopathy (hypothyroidism, hyperadrenocorticism)
• Drug-induced myopathy (corticosteroids, statins)
• Paraneoplastic myopathy (thymoma, other neoplasia)

The clinical utility of neostigmine administration in the diagnosis of acquired myasthenia gravis has been documented, and this test may help differentiate myasthenia gravis from polymyositis in cases with prominent weakness.

Neosporosis and hammondiosis in dogs are infectious causes of myositis that should be considered, particularly in young dogs or those with appropriate geographic exposure.

Management and Treatment

Corticosteroid Therapy

Immunosuppressive doses of prednisone or prednisolone are the cornerstone of initial therapy. The goal is to suppress the inflammatory response and halt muscle fiber destruction. Clinical improvement is typically observed within 2 to 4 weeks of initiating therapy, with reduced weakness, improved gait, and resolution of dysphagia.

Response to therapy should be monitored through serial clinical examinations and serum CK measurements. Once clinical remission is achieved, the corticosteroid dose should be gradually tapered over several months to the lowest effective dose. Some dogs may require long-term maintenance therapy, while others may achieve complete remission and discontinue treatment.

Adjunctive Immunosuppressive Agents

For dogs that do not respond adequately to corticosteroids alone, or for those requiring high maintenance doses, adjunctive immunosuppressive agents should be considered. Options include:

• Azathioprine
• Mycophenolate mofetil
• Cyclosporine
• Leflunomide

These agents allow for corticosteroid dose reduction and may improve long-term outcomes. The choice of agent depends on individual patient factors, cost, and clinician experience.

Physical Rehabilitation

Physical therapy is an essential component of the management plan. Controlled exercise, passive range of motion exercises, and therapeutic modalities such as neuromuscular electrical stimulation can help maintain muscle mass, improve strength, and prevent contractures. A structured rehabilitation program should be tailored to the individual dog's capabilities and adjusted as clinical status improves.

Nutritional Support

Dysphagia and regurgitation may compromise nutritional intake. Affected dogs may require dietary modifications, including elevated feeding stations, softened food, or hand feeding. In severe cases, temporary enteral nutrition via nasogastric or esophagostomy tube may be necessary to maintain body condition.

Monitoring and Follow-up

Regular monitoring is essential to assess treatment response and detect adverse effects. Recommended monitoring includes:

• Monthly clinical examinations during the induction phase
• Serum CK measurements every 4 to 6 weeks
• Complete blood count and biochemistry profile every 3 to 6 months
• Urinalysis for proteinuria (corticosteroid-induced)
• Body weight and body condition score assessment

Prognosis and Outcomes

The prognosis for canine polymyositis is variable and depends on the severity of disease at presentation, response to therapy, and presence of concurrent disorders. With appropriate immunosuppressive therapy, many dogs achieve clinical remission and maintain good quality of life. However, some dogs may experience relapses during dose reduction or develop adverse effects from long-term immunosuppression.

Poor prognostic indicators include:

• Severe muscle atrophy at presentation
• Marked dysphagia with aspiration pneumonia
• Concurrent megaesophagus
• Poor response to initial therapy
• Underlying neoplasia (thymoma)

Canine thymoma has been associated with paraneoplastic polymyositis, and identification of an underlying thymoma carries its own prognostic and therapeutic implications.

Common Failure Patterns

Delayed Diagnosis

Failure to recognize polymyositis early in the disease course is a common pitfall. Dogs presenting with vague weakness or exercise intolerance may be misdiagnosed with orthopedic disease, degenerative myelopathy, or generalized debility. A thorough neurologic examination and serum CK measurement should be performed in any dog with unexplained weakness.

Inadequate Immunosuppression

Insufficient immunosuppressive doses or premature dose reduction can lead to treatment failure. The goal of initial therapy is to achieve rapid and complete suppression of inflammation. Doses should be maintained at immunosuppressive levels until clinical remission is achieved, then tapered slowly over months.

Failure to Identify Underlying Disease

Polymyositis may be secondary to underlying conditions such as thymoma, other neoplasia, or concurrent immune-mediated disorders. A thorough diagnostic workup, including thoracic imaging and abdominal ultrasound, should be performed to identify potential underlying causes.

Neglecting Physical Rehabilitation

Medical therapy alone may not restore full muscle function, particularly in dogs with significant atrophy. Physical rehabilitation is essential for optimal recovery and should be initiated early in the treatment course.

Records and Measurements

Clinical Assessment Tools

Objective assessment of muscle strength and function is important for monitoring disease progression and treatment response. The following parameters should be documented at each visit:

• Gait assessment (normal, mild weakness, moderate weakness, non-ambulatory)
• Ability to rise from recumbency (unassisted, requires assistance, unable)
• Muscle mass scoring (0 to 3 scale for temporal, masseter, epaxial, and limb muscles)
• Dysphagia assessment (normal, mild difficulty, moderate difficulty, unable to swallow)
• Body weight and body condition score

Laboratory Monitoring

Serial serum CK measurements provide objective evidence of muscle inflammation. A decreasing CK trend indicates response to therapy, while rising CK may signal relapse or inadequate immunosuppression. Complete blood count and biochemistry profile should be monitored for adverse effects of immunosuppressive medications.

Treatment Response Criteria

Response to therapy should be categorized as:

• Complete remission: Normal gait, no weakness, normal CK, no dysphagia
• Partial remission: Improved but persistent weakness or CK elevation
• No response: No improvement after 4 weeks of adequate therapy
• Relapse: Worsening after initial improvement

Professional Escalation Criteria

Urgent Veterinary Referral

Immediate referral to a veterinary neurologist or internal medicine specialist is indicated for:

• Dogs with severe dysphagia and suspected aspiration pneumonia
• Dogs with acute onset of non-ambulatory weakness
• Dogs with suspected megaesophagus and regurgitation
• Dogs with respiratory difficulty or cyanosis
• Dogs with suspected thymoma or other neoplasia

Routine Referral

Referral should be considered for:

• Dogs that fail to respond to 4 weeks of adequate immunosuppressive therapy
• Dogs requiring muscle biopsy for definitive diagnosis
• Dogs with complex concurrent medical conditions
• Dogs requiring advanced imaging (MRI) for diagnosis
• Dogs with recurrent relapses during dose reduction

Practical Decision Framework for Canine Polymyositis Management

Treatment Response Stratification and Protocol Adjustment

Managing canine polymyositis requires a structured approach to treatment decisions based on objective clinical and laboratory parameters. The following decision framework provides a systematic method for evaluating treatment response and adjusting therapy, which complements the general management principles described in the preceding sections.

Initial Treatment Phase (Weeks 0 to 4)

The first four weeks of immunosuppressive therapy represent the induction phase, during which the primary goal is rapid suppression of muscle inflammation. Prednisone or prednisolone is initiated at immunosuppressive doses of 2 to 4 mg/kg per day, divided into two doses. This dosing range is consistent with standard recommendations for immune-mediated myopathies in dogs, as referenced in the Merck Veterinary Manual.

During this phase, the clinician should establish baseline measurements for the following parameters:

• Serum CK concentration
• Gait assessment score (0 to 4 scale)
• Muscle mass score (0 to 3 scale for each muscle group)
• Dysphagia severity grade (0 to 3)
• Body weight and body condition score
• Owner-reported activity level (daily walks, stair climbing, playing)

Weekly recheck examinations during the first month allow for early detection of adverse effects and assessment of initial response. Serum CK should be measured at each visit, as it provides the most objective biochemical indicator of ongoing muscle inflammation.

Response Categories and Corresponding Actions

After four weeks of adequate immunosuppressive therapy, the clinician should categorize the patient's response using the following criteria:

Complete Response (CR)

• Normal gait with no detectable weakness
• Serum CK within reference range
• No dysphagia
• Owner reports return to normal activity levels
• Muscle mass may still be reduced but is stable or improving

Action: Begin gradual corticosteroid taper. Reduce the total daily dose by 25% every 2 to 4 weeks, monitoring for relapse at each dose reduction. The taper should proceed slowly over 4 to 6 months to maintain remission.

Partial Response (PR)

• Improved gait but persistent mild weakness
• Serum CK decreased by at least 50% from baseline but still elevated
• Dysphagia improved but not resolved
• Owner reports increased activity but not full return to normal

Action: Maintain current corticosteroid dose for an additional 2 to 4 weeks. If improvement continues, begin taper as above. If no further improvement after 4 additional weeks, consider adding an adjunctive immunosuppressive agent such as azathioprine or mycophenolate mofetil.

No Response (NR)

• No improvement in gait, weakness, or dysphagia
• Serum CK unchanged or increased
• Owner reports no change in clinical signs

Action: Re-evaluate the diagnosis. Consider the following possibilities:

• Incorrect diagnosis (reconsider differentials including myasthenia gravis, infectious myositis, muscular dystrophy)
• Inadequate immunosuppressive dose (consider increasing prednisone dose or switching to dexamethasone)
• Concurrent infection (Neospora caninum, Toxoplasma gondii, bacterial myositis)
• Underlying neoplasia (thymoma, other paraneoplastic syndromes)
• Drug malabsorption or non-compliance

If the diagnosis remains confirmed, add an adjunctive immunosuppressive agent and consider referral to a veterinary neurologist or internal medicine specialist. The clinicopathologic review of 200 cases of canine inflammatory myopathies provides context for expected response rates and the frequency of treatment modifications.

Relapse (RL)

• Worsening of clinical signs after initial improvement
• Rising serum CK after previous decrease
• Return of dysphagia or weakness

Action: Increase corticosteroid dose to the previously effective level or higher. If the relapse occurred during a taper, return to the last effective dose and taper more slowly. If the relapse occurred while on a stable dose, consider adding an adjunctive agent.

Record System for Longitudinal Monitoring

A structured record system is essential for tracking disease progression, treatment response, and adverse effects over time. The following template provides a framework for consistent documentation at each visit.

Visit Documentation Template

Date: ___________ Visit Number: ___________

Subjective Assessment (Owner Report)

• Activity level (0 = normal, 1 = mildly reduced, 2 = moderately reduced, 3 = severely reduced)
• Appetite (0 = normal, 1 = reduced, 2 = increased)
• Dysphagia (0 = none, 1 = occasional gagging, 2 = frequent difficulty, 3 = unable to swallow)
• Regurgitation (0 = none, 1 = occasional, 2 = frequent)
• Adverse effects noted (polyuria, polydipsia, panting, diarrhea, vomiting)

Objective Assessment (Clinician Examination)

• Gait score (0 = normal, 1 = mild stiffness, 2 = moderate weakness, 3 = severe weakness, 4 = non-ambulatory)
• Ability to rise (0 = unassisted, 1 = requires one attempt, 2 = requires multiple attempts, 3 = unable)
• Muscle mass score (0 = normal, 1 = mild atrophy, 2 = moderate atrophy, 3 = severe atrophy) for each: temporal, masseter, epaxial, proximal limb
• Dysphagia assessment (0 = normal, 1 = mild difficulty, 2 = moderate difficulty, 3 = unable)
• Body weight (kg): ___________
• Body condition score (1 to 9): ___________

Laboratory Data

• Serum CK (U/L): ___________ (reference range: ___________)
• AST (U/L): ___________
• ALT (U/L): ___________
• Creatinine (mg/dL): ___________
• BUN (mg/dL): ___________
• Urine protein:creatinine ratio: ___________ (if indicated)
• Complete blood count: WBC ___________, HCT ___________, platelets ___________

Current Medications

• Prednisone dose (mg/kg/day): ___________
• Adjunctive agent and dose: ___________
• Other medications: ___________

Treatment Response Category

• Complete response
• Partial response
• No response
• Relapse

Plan

• Continue current dose
• Increase dose to: ___________
• Decrease dose to: ___________
• Add adjunctive agent: ___________
• Schedule recheck in: ___________ weeks
• Refer to specialist

Serial Data Tracking Sheet

A separate tracking sheet should be maintained for each patient, allowing the clinician to visualize trends over time. The following parameters should be plotted or recorded at each visit:

This tracking system allows the clinician to identify trends that may not be apparent from individual visit data. For example, a gradual increase in CK over several visits may precede clinical relapse by weeks, allowing for preemptive dose adjustment.

Troubleshooting Common Treatment Challenges

Challenge 1: Poor Initial Response to Corticosteroids

When a dog shows no improvement after four weeks of adequate corticosteroid therapy, the clinician must systematically evaluate potential causes.

Step 1: Verify the diagnosis. Review the muscle biopsy histopathology to confirm inflammatory myopathy. Consider whether the biopsy sample was adequate and whether it was interpreted by a pathologist experienced in neuromuscular disease. If the diagnosis is uncertain, repeat muscle biopsy from a different site may be indicated.

Step 2: Rule out infectious causes. Serologic testing for Neospora caninum and Toxoplasma gondii should be performed, as these protozoal infections can cause myositis that may worsen with corticosteroid therapy. The relationship between neosporosis and hammondiosis in dogs has been documented, and these infectious causes should be considered in young dogs or those with appropriate geographic exposure.

Step 3: Assess for underlying neoplasia. Thoracic radiographs and abdominal ultrasound should be performed to evaluate for thymoma or other neoplasms. Canine thymoma has been associated with paraneoplastic polymyositis, and identification of an underlying thymoma carries its own prognostic and therapeutic implications.

Step 4: Consider alternative immunosuppressive strategies. If the diagnosis is confirmed and infectious causes are ruled out, options include:

• Switching from prednisone to dexamethasone (0.2 to 0.4 mg/kg/day)
• Adding an adjunctive immunosuppressive agent
• Considering pulse corticosteroid therapy (methylprednisolone sodium succinate 10 to 20 mg/kg IV once daily for 1 to 3 days)

Challenge 2: Recurrent Relapses During Dose Taper

Some dogs experience repeated relapses as the corticosteroid dose is reduced. This pattern suggests that the underlying immune response is not fully suppressed and that a more gradual taper or additional immunosuppression is needed.

Step 1: Return to the last effective dose. Increase the corticosteroid dose to the level at which the dog was last in remission. Maintain this dose for 4 to 8 weeks before attempting another taper.

Step 2: Slow the taper rate. Instead of reducing the dose by 25% every 2 to 4 weeks, reduce by 10 to 15% every 4 to 6 weeks. Some dogs require extremely slow tapers over 6 to 12 months.

Step 3: Add an adjunctive immunosuppressive agent. Azathioprine (2 mg/kg once daily or every other day) or mycophenolate mofetil (10 to 20 mg/kg twice daily) can be added to allow for lower corticosteroid doses. The adjunctive agent should be given for 4 to 8 weeks before attempting further corticosteroid reduction.

Step 4: Evaluate for concurrent disease. Relapses may be triggered by intercurrent illness, stress, or environmental factors. Address any underlying conditions and consider stress reduction strategies.

Challenge 3: Corticosteroid Adverse Effects

Long-term corticosteroid therapy carries significant risks, including iatrogenic hyperadrenocorticism, diabetes mellitus, proteinuria, and increased susceptibility to infections.

Step 1: Monitor for adverse effects. At each visit, assess for polyuria, polydipsia, polyphagia, panting, and weight gain. Perform urinalysis for proteinuria every 3 to 6 months. Monitor blood glucose and blood pressure periodically.

Step 2: Minimize corticosteroid dose. The goal of therapy is to use the lowest effective dose. Adjunctive immunosuppressive agents should be added early in dogs that require high maintenance doses.

Step 3: Address specific adverse effects.

• Proteinuria: Consider angiotensin-converting enzyme inhibitors (enalapril 0.5 mg/kg once daily)
• Diabetes mellitus: Manage with insulin therapy and dietary modification
• Urinary tract infections: Culture and treat as needed
• Gastrointestinal ulceration: Consider gastroprotectants if clinical signs develop

Step 4: Consider alternative corticosteroid-sparing protocols. In dogs that cannot tolerate corticosteroids, protocols using cyclosporine or leflunomide alone may be considered, though evidence for their efficacy in polymyositis is limited.

Challenge 4: Persistent Dysphagia

Dysphagia is a critical clinical sign that increases the risk of aspiration pneumonia. Dogs with persistent dysphagia require aggressive management.

Step 1: Assess swallowing function. Perform a swallowing assessment by offering small amounts of water and food. Observe for gagging, coughing, or regurgitation. If aspiration is suspected, thoracic radiographs should be obtained.

Step 2: Modify feeding practices.

• Elevate food and water bowls to reduce gravitational challenges
• Offer softened or pureed food
• Hand feed small amounts frequently
• Consider temporary enteral nutrition via nasogastric or esophagostomy tube

Step 3: Monitor for aspiration pneumonia. Clinical signs include coughing, fever, lethargy, and increased respiratory effort. Thoracic radiographs should be obtained if aspiration is suspected. Treatment includes broad-spectrum antibiotics and supportive care.

Step 4: Escalate immunosuppression. Persistent dysphagia indicates ongoing muscle inflammation. Consider increasing the corticosteroid dose or adding an adjunctive agent. If dysphagia does not improve within 2 to 4 weeks of intensified therapy, referral to a specialist is indicated.

Comparison of Adjunctive Immunosuppressive Agents

When corticosteroid therapy alone is insufficient, the clinician must choose among several adjunctive immunosuppressive agents. The following comparison provides guidance for agent selection based on individual patient factors.

Selection Considerations:

• Azathioprine is the most commonly used adjunctive agent due to its low cost and established safety profile. It is a reasonable first choice for most dogs, though the delayed onset of action (4 to 6 weeks) must be considered.

• Mycophenolate mofetil has a faster onset of action (2 to 4 weeks) and may be preferred in dogs with more severe disease. However, gastrointestinal adverse effects are common and may limit tolerability.

• Cyclosporine is effective but expensive. It may be considered in dogs that cannot tolerate azathioprine or mycophenolate. Therapeutic drug monitoring is recommended to ensure adequate blood levels.

• Leflunomide is less commonly used but may be effective in some cases. Its long half-life allows for once-daily dosing.

Physical Rehabilitation Protocol

Physical rehabilitation is an essential component of the management plan, yet it is often underutilized. The following protocol provides a structured approach to rehabilitation that can be implemented in general practice.

Phase 1: Acute Phase (Weeks 0 to 4)

During the initial treatment phase, the goal of rehabilitation is to maintain joint range of motion and prevent contractures without exacerbating muscle inflammation.

• Passive range of motion exercises: 10 repetitions per joint, twice daily
• Gentle massage of affected muscle groups
• Assisted standing exercises (5 to 10 minutes, 2 to 3 times daily)
• No forced exercise or strenuous activity

Phase 2: Recovery Phase (Weeks 4 to 12)

As clinical signs improve, rehabilitation can be intensified to rebuild muscle mass and strength.

• Controlled leash walks: 5 to 10 minutes, 2 to 3 times daily
• Slow stair climbing (3 to 5 steps, 2 to 3 times daily)
• Balance exercises (standing on uneven surfaces)
• Neuromuscular electrical stimulation (if available)
• Hydrotherapy (if available and tolerated)

Phase 3: Maintenance Phase (After Week 12)

Once remission is achieved, the focus shifts to maintaining muscle function and preventing relapse.

• Regular exercise: 20 to 30 minutes of controlled activity daily
• Continued passive range of motion for atrophied muscles
• Owner education on recognizing early signs of relapse
• Gradual return to normal activity as tolerated

Professional Escalation Criteria

The following criteria should prompt consideration of referral to a veterinary neurologist or internal medicine specialist:

Urgent Referral (within 24 to 48 hours)

• Acute onset of non-ambulatory weakness
• Severe dysphagia with suspected aspiration pneumonia
• Respiratory difficulty or cyanosis
• Suspected megaesophagus with regurgitation
• Seizures or altered mentation suggesting central nervous system involvement

Routine Referral (within 1 to 2 weeks)

• No response to 4 weeks of adequate immunosuppressive therapy
• Recurrent relapses during dose reduction
• Need for muscle biopsy or advanced imaging (MRI)
• Complex concurrent medical conditions
• Suspected underlying neoplasia requiring further workup
• Adverse effects that limit treatment options

The American College of Veterinary Internal Medicine provides resources for locating board-certified specialists in veterinary neurology and internal medicine. The American Animal Hospital Association also offers guidelines for referral and collaborative care in complex medical cases.

Practical Decision Framework for Canine Polymyositis Management

Treatment Response Stratification and Protocol Adjustment

Managing canine polymyositis requires a structured approach to treatment decisions based on objective clinical and laboratory parameters. The following decision framework provides a systematic method for evaluating treatment response and adjusting therapy, which complements the general management principles described in the preceding sections.

Initial Treatment Phase (Weeks 0 to 4)

The first four weeks of immunosuppressive therapy represent the induction phase, during which the primary goal is rapid suppression of muscle inflammation. Prednisone or prednisolone is initiated at immunosuppressive doses of 2 to 4 mg/kg per day, divided into two doses. This dosing range is consistent with standard recommendations for immune-mediated myopathies in dogs, as referenced in the Merck Veterinary Manual.

During this phase, the clinician should establish baseline measurements for the following parameters:

• Serum CK concentration
• Gait assessment score (0 to 4 scale)
• Muscle mass score (0 to 3 scale for each muscle group)
• Dysphagia severity grade (0 to 3)
• Body weight and body condition score
• Owner-reported activity level (daily walks, stair climbing, playing)

Weekly recheck examinations during the first month allow for early detection of adverse effects and assessment of initial response. Serum CK should be measured at each visit, as it provides the most objective biochemical indicator of ongoing muscle inflammation.

Response Categories and Corresponding Actions

After four weeks of adequate immunosuppressive therapy, the clinician should categorize the patient's response using the following criteria:

Complete Response (CR)

• Normal gait with no detectable weakness
• Serum CK within reference range
• No dysphagia
• Owner reports return to normal activity levels
• Muscle mass may still be reduced but is stable or improving

Action: Begin gradual corticosteroid taper. Reduce the total daily dose by 25% every 2 to 4 weeks, monitoring for relapse at each dose reduction. The taper should proceed slowly over 4 to 6 months to maintain remission.

Partial Response (PR)

• Improved gait but persistent mild weakness
• Serum CK decreased by at least 50% from baseline but still elevated
• Dysphagia improved but not resolved
• Owner reports increased activity but not full return to normal

Action: Maintain current corticosteroid dose for an additional 2 to 4 weeks. If improvement continues, begin taper as above. If no further improvement after 4 additional weeks, consider adding an adjunctive immunosuppressive agent such as azathioprine or mycophenolate mofetil.

No Response (NR)

• No improvement in gait, weakness, or dysphagia
• Serum CK unchanged or increased
• Owner reports no change in clinical signs

Action: Re-evaluate the diagnosis. Consider the following possibilities:

• Incorrect diagnosis (reconsider differentials including myasthenia gravis, infectious myositis, muscular dystrophy)
• Inadequate immunosuppressive dose (consider increasing prednisone dose or switching to dexamethasone)
• Concurrent infection (Neospora caninum, Toxoplasma gondii, bacterial myositis)
• Underlying neoplasia (thymoma, other paraneoplastic syndromes)
• Drug malabsorption or non-compliance

If the diagnosis remains confirmed, add an adjunctive immunosuppressive agent and consider referral to a veterinary neurologist or internal medicine specialist. The clinicopathologic review of 200 cases of canine inflammatory myopathies provides context for expected response rates and the frequency of treatment modifications.

Relapse (RL)

• Worsening of clinical signs after initial improvement
• Rising serum CK after previous decrease
• Return of dysphagia or weakness

Action: Increase corticosteroid dose to the previously effective level or higher. If the relapse occurred during a taper, return to the last effective dose and taper more slowly. If the relapse occurred while on a stable dose, consider adding an adjunctive agent.

Record System for Longitudinal Monitoring

A structured record system is essential for tracking disease progression, treatment response, and adverse effects over time. The following template provides a framework for consistent documentation at each visit.

Visit Documentation Template

Date: ___________ Visit Number: ___________

Subjective Assessment (Owner Report)

• Activity level (0 = normal, 1 = mildly reduced, 2 = moderately reduced, 3 = severely reduced)
• Appetite (0 = normal, 1 = reduced, 2 = increased)
• Dysphagia (0 = none, 1 = occasional gagging, 2 = frequent difficulty, 3 = unable to swallow)
• Regurgitation (0 = none, 1 = occasional, 2 = frequent)
• Adverse effects noted (polyuria, polydipsia, panting, diarrhea, vomiting)

Objective Assessment (Clinician Examination)

• Gait score (0 = normal, 1 = mild stiffness, 2 = moderate weakness, 3 = severe weakness, 4 = non-ambulatory)
• Ability to rise (0 = unassisted, 1 = requires one attempt, 2 = requires multiple attempts, 3 = unable)
• Muscle mass score (0 = normal, 1 = mild atrophy, 2 = moderate atrophy, 3 = severe atrophy) for each: temporal, masseter, epaxial, proximal limb
• Dysphagia assessment (0 = normal, 1 = mild difficulty, 2 = moderate difficulty, 3 = unable)
• Body weight (kg): ___________
• Body condition score (1 to 9): ___________

Laboratory Data

• Serum CK (U/L): ___________ (reference range: ___________)
• AST (U/L): ___________
• ALT (U/L): ___________
• Creatinine (mg/dL): ___________
• BUN (mg/dL): ___________
• Urine protein:creatinine ratio: ___________ (if indicated)
• Complete blood count: WBC ___________, HCT ___________, platelets ___________

Current Medications

• Prednisone dose (mg/kg/day): ___________
• Adjunctive agent and dose: ___________
• Other medications: ___________

Treatment Response Category

• Complete response
• Partial response
• No response
• Relapse

Plan

• Continue current dose
• Increase dose to: ___________
• Decrease dose to: ___________
• Add adjunctive agent: ___________
• Schedule recheck in: ___________ weeks
• Refer to specialist

Serial Data Tracking Sheet

A separate tracking sheet should be maintained for each patient, allowing the clinician to visualize trends over time. The following parameters should be plotted or recorded at each visit:

This tracking system allows the clinician to identify trends that may not be apparent from individual visit data. For example, a gradual increase in CK over several visits may precede clinical relapse by weeks, allowing for preemptive dose adjustment.

Troubleshooting Common Treatment Challenges

Challenge 1: Poor Initial Response to Corticosteroids

When a dog shows no improvement after four weeks of adequate corticosteroid therapy, the clinician must systematically evaluate potential causes.

Step 1: Verify the diagnosis. Review the muscle biopsy histopathology to confirm inflammatory myopathy. Consider whether the biopsy sample was adequate and whether it was interpreted by a pathologist experienced in neuromuscular disease. If the diagnosis is uncertain, repeat muscle biopsy from a different site may be indicated.

Step 2: Rule out infectious causes. Serologic testing for Neospora caninum and Toxoplasma gondii should be performed, as these protozoal infections can cause myositis that may worsen with corticosteroid therapy. The relationship between neosporosis and hammondiosis in dogs has been documented, and these infectious causes should be considered in young dogs or those with appropriate geographic exposure.

Step 3: Assess for underlying neoplasia. Thoracic radiographs and abdominal ultrasound should be performed to evaluate for thymoma or other neoplasms. Canine thymoma has been associated with paraneoplastic polymyositis, and identification of an underlying thymoma carries its own prognostic and therapeutic implications.

Step 4: Consider alternative immunosuppressive strategies. If the diagnosis is confirmed and infectious causes are ruled out, options include:

• Switching from prednisone to dexamethasone (0.2 to 0.4 mg/kg/day)
• Adding an adjunctive immunosuppressive agent
• Considering pulse corticosteroid therapy (methylprednisolone sodium succinate 10 to 20 mg/kg IV once daily for 1 to 3 days)

Challenge 2: Recurrent Relapses During Dose Taper

Some dogs experience repeated relapses as the corticosteroid dose is reduced. This pattern suggests that the underlying immune response is not fully suppressed and that a more gradual taper or additional immunosuppression is needed.

Step 1: Return to the last effective dose. Increase the corticosteroid dose to the level at which the dog was last in remission. Maintain this dose for 4 to 8 weeks before attempting another taper.

Step 2: Slow the taper rate. Instead of reducing the dose by 25% every 2 to 4 weeks, reduce by 10 to 15% every 4 to 6 weeks. Some dogs require extremely slow tapers over 6 to 12 months.

Step 3: Add an adjunctive immunosuppressive agent. Azathioprine (2 mg/kg once daily or every other day) or mycophenolate mofetil (10 to 20 mg/kg twice daily) can be added to allow for lower corticosteroid doses. The adjunctive agent should be given for 4 to 8 weeks before attempting further corticosteroid reduction.

Step 4: Evaluate for concurrent disease. Relapses may be triggered by intercurrent illness, stress, or environmental factors. Address any underlying conditions and consider stress reduction strategies.

Challenge 3: Corticosteroid Adverse Effects

Long-term corticosteroid therapy carries significant risks, including iatrogenic hyperadrenocorticism, diabetes mellitus, proteinuria, and increased susceptibility to infections.

Step 1: Monitor for adverse effects. At each visit, assess for polyuria, polydipsia, polyphagia, panting, and weight gain. Perform urinalysis for proteinuria every 3 to 6 months. Monitor blood glucose and blood pressure periodically.

Step 2: Minimize corticosteroid dose. The goal of therapy is to use the lowest effective dose. Adjunctive immunosuppressive agents should be added early in dogs that require high maintenance doses.

Step 3: Address specific adverse effects.

• Proteinuria: Consider angiotensin-converting enzyme inhibitors (enalapril 0.5 mg/kg once daily)
• Diabetes mellitus: Manage with insulin therapy and dietary modification
• Urinary tract infections: Culture and treat as needed
• Gastrointestinal ulceration: Consider gastroprotectants if clinical signs develop

Step 4: Consider alternative corticosteroid-sparing protocols. In dogs that cannot tolerate corticosteroids, protocols using cyclosporine or leflunomide alone may be considered, though evidence for their efficacy in polymyositis is limited.

Challenge 4: Persistent Dysphagia

Dysphagia is a critical clinical sign that increases the risk of aspiration pneumonia. Dogs with persistent dysphagia require aggressive management.

Step 1: Assess swallowing function. Perform a swallowing assessment by offering small amounts of water and food. Observe for gagging, coughing, or regurgitation. If aspiration is suspected, thoracic radiographs should be obtained.

Step 2: Modify feeding practices.

• Elevate food and water bowls to reduce gravitational challenges
• Offer softened or pureed food
• Hand feed small amounts frequently
• Consider temporary enteral nutrition via nasogastric or esophagostomy tube

Step 3: Monitor for aspiration pneumonia. Clinical signs include coughing, fever, lethargy, and increased respiratory effort. Thoracic radiographs should be obtained if aspiration is suspected. Treatment includes broad-spectrum antibiotics and supportive care.

Step 4: Escalate immunosuppression. Persistent dysphagia indicates ongoing muscle inflammation. Consider increasing the corticosteroid dose or adding an adjunctive agent. If dysphagia does not improve within 2 to 4 weeks of intensified therapy, referral to a specialist is indicated.

Comparison of Adjunctive Immunosuppressive Agents

When corticosteroid therapy alone is insufficient, the clinician must choose among several adjunctive immunosuppressive agents. The following comparison provides guidance for agent selection based on individual patient factors.

Selection Considerations:

• Azathioprine is the most commonly used adjunctive agent due to its low cost and established safety profile. It is a reasonable first choice for most dogs, though the delayed onset of action (4 to 6 weeks) must be considered.

• Mycophenolate mofetil has a faster onset of action (2 to 4 weeks) and may be preferred in dogs with more severe disease. However, gastrointestinal adverse effects are common and may limit tolerability.

• Cyclosporine is effective but expensive. It may be considered in dogs that cannot tolerate azathioprine or mycophenolate. Therapeutic drug monitoring is recommended to ensure adequate blood levels.

• Leflunomide is less commonly used but may be effective in some cases. Its long half-life allows for once-daily dosing.

Physical Rehabilitation Protocol

Physical rehabilitation is an essential component of the management plan, yet it is often underutilized. The following protocol provides a structured approach to rehabilitation that can be implemented in general practice.

Phase 1: Acute Phase (Weeks 0 to 4)

During the initial treatment phase, the goal of rehabilitation is to maintain joint range of motion and prevent contractures without exacerbating muscle inflammation.

• Passive range of motion exercises: 10 repetitions per joint, twice daily
• Gentle massage of affected muscle groups
• Assisted standing exercises (5 to 10 minutes, 2 to 3 times daily)
• No forced exercise or strenuous activity

Phase 2: Recovery Phase (Weeks 4 to 12)

As clinical signs improve, rehabilitation can be intensified to rebuild muscle mass and strength.

• Controlled leash walks: 5 to 10 minutes, 2 to 3 times daily
• Slow stair climbing (3 to 5 steps, 2 to 3 times daily)
• Balance exercises (standing on uneven surfaces)
• Neuromuscular electrical stimulation (if available)
• Hydrotherapy (if available and tolerated)

Phase 3: Maintenance Phase (After Week 12)

Once remission is achieved, the focus shifts to maintaining muscle function and preventing relapse.

• Regular exercise: 20 to 30 minutes of controlled activity daily
• Continued passive range of motion for atrophied muscles
• Owner education on recognizing early signs of relapse
• Gradual return to normal activity as tolerated

Professional Escalation Criteria

The following criteria should prompt consideration of referral to a veterinary neurologist or internal medicine specialist:

Urgent Referral (within 24 to 48 hours)

• Acute onset of non-ambulatory weakness
• Severe dysphagia with suspected aspiration pneumonia
• Respiratory difficulty or cyanosis
• Suspected megaesophagus with regurgitation
• Seizures or altered mentation suggesting central nervous system involvement

Routine Referral (within 1 to 2 weeks)

• No response to 4 weeks of adequate immunosuppressive therapy
• Recurrent relapses during dose reduction
• Need for muscle biopsy or advanced imaging (MRI)
• Complex concurrent medical conditions
• Suspected underlying neoplasia requiring further workup
• Adverse effects that limit treatment options

The American College of Veterinary Internal Medicine provides resources for locating board-certified specialists in veterinary neurology and internal medicine. The American Animal Hospital Association also offers guidelines for referral and collaborative care in complex medical cases.

Frequently Asked Questions

What is the difference between polymyositis and masticatory muscle myositis?

Polymyositis is a generalized inflammatory myopathy affecting multiple muscle groups throughout the body, including limb muscles, axial muscles, and muscles involved in swallowing. Masticatory muscle myositis is a specific immune-mediated myopathy that selectively targets the type 2M fibers found only in the muscles of mastication (temporal, masseter, and pterygoid muscles). Dogs with masticatory muscle myositis typically present with swelling and pain of the jaw muscles initially, followed by severe atrophy, while polymyositis causes generalized weakness and dysphagia.

Can polymyositis be cured?

Polymyositis is typically managed instead of cured. With appropriate immunosuppressive therapy, many dogs achieve clinical remission and can maintain good quality of life. Some dogs may eventually discontinue medication and remain in remission, while others require long-term maintenance therapy. Relapses can occur, particularly during dose reduction or in response to stress.

How long does it take for dogs to respond to treatment?

Clinical improvement is typically observed within 2 to 4 weeks of initiating immunosuppressive therapy. Owners may notice improved energy, better gait, and reduced dysphagia. Serum CK levels should begin to decrease within this timeframe. Complete remission may take several months to achieve, and gradual dose reduction should not begin until remission is established.

What are the side effects of immunosuppressive therapy?

Corticosteroids can cause polyuria, polydipsia, polyphagia, weight gain, panting, and increased susceptibility to infections. Long-term use may lead to iatrogenic hyperadrenocorticism, diabetes mellitus, and proteinuria. Azathioprine can cause bone marrow suppression, hepatotoxicity, and gastrointestinal upset. Mycophenolate mofetil may cause diarrhea and vomiting. Regular monitoring is essential to detect and manage these adverse effects.

Is polymyositis painful?

Polymyositis is not typically painful, though affected dogs may experience discomfort from muscle inflammation. The primary clinical signs are weakness and muscle atrophy instead of pain. However, some dogs may show signs of muscle pain or stiffness, particularly during the acute phase. This contrasts with conditions like masticatory muscle myositis, which can be painful during the acute inflammatory stage.

Can polymyositis affect the heart?

While polymyositis primarily affects skeletal muscle, cardiac muscle involvement has been reported in some cases. Myocarditis can lead to arrhythmias, conduction disturbances, and myocardial dysfunction. Electrocardiography and echocardiography should be considered in dogs with clinical signs of cardiac disease or in those with severe, generalized myositis.

What is the role of physical therapy in management?

Physical therapy is essential for maintaining muscle mass, preventing contractures, and improving functional recovery. Controlled exercise, passive range of motion, and therapeutic modalities help preserve muscle function while medical therapy controls inflammation. A structured rehabilitation program should be initiated early and adjusted as the dog's clinical status improves.

When should I consider referral to a specialist?

Referral to a veterinary neurologist or internal medicine specialist should be considered when the diagnosis is uncertain, when initial therapy fails, or when complications such as aspiration pneumonia or megaesophagus develop. Specialists can perform advanced diagnostic testing, including EMG, muscle biopsy interpretation, and MRI, and can guide complex immunosuppressive regimens.

Related Veterinary Guides

• Dog
• Dog Shedding Management
• How To Skin A Dog
• Arthritis In Dogs Symptoms And Diagnosis
• Canine Hyperadrenocorticism Cushings Diagnostic Management

References and Further Reading

• www.merckvetmanual.com
• www.aaha.org
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Polymyositis in dogs.. Journal of the American Veterinary Medical Association, 1980.
• The clinical utility of neostigmine administration in the diagnosis of acquired myasthenia gravis.. Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001), 2021.
• Canine inflammatory myopathies: a clinicopathologic review of 200 cases.. Journal of veterinary internal medicine, 2004.
• Canine thymoma.. The Veterinary clinics of North America. Small animal practice, 1985.
• Inflammatory myopathies.. The Veterinary clinics of North America. Small animal practice, 2002.
• Neosporosis and hammondiosis in dogs.. The Journal of small animal practice, 2007.
• Polymyositis in dogs. Journal of the American Veterinary Medical Association, 1980.
• Magnetic Resonance Imaging Characteristics of Hereditary Polymyositis in the Dutch Kooiker Dog. Pets, 2025.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.